DiscoveryBioMed, Inc. has agreed to move forward with a "service" contract for primary human cell bioassay testing for its first commercial client, Lifeline Cell Technology, Inc., a wholly owned subsidiary of International Stem Cell Corporation (OTCBB: ISCO).
"This is a mutually beneficial relationship between two companies that believe in the development, use, and sale of cell physiology as well as early revenue." as the most important and biologically relevant reagents for experimental systems," said Dr. Erik Schwiebert, CEO of DBM, Inc. "Lifeline is also our first commercial client and these contracts provide a wonderful opportunity for our company to generate knowledge about human
"We agree that human cells are critically important in-vitro models to assure drug safety and conduct basic research," said ISCO President and Lifeline Cell Technology CEO Jeffrey Janus. "DiscoveryBioMed's proven expertise in assay development combined with Lifeline's expertise in producing optimized human adult and will certainly result in powerful research tools."
In addition to these introductory interactions, DBM and Lifeline Cell Tech are developing a mutual SBIR grant proposal on the use of multiple derived from different tissues as an important in vitro platform for testing pollutant, candidate therapeutics and existing drugs for toxicity against cells in a variety of human tissues.
ABOUT DISCOVERYBIOMED, INC.
DiscoveryBioMed, Inc. is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and drug discovery. The company is located within Innovation Depot in Birmingham. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, it focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its "fee-for-service" support to researchers in allied areas and currently serves clients both locally in Alabama as well as in 8 other states in the US currently. For more information, visit the DBM website at www.discoverybiomed.com.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human www.internationalstemcell.com. from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true " " and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at:
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
For more news and information on International Stem Cell Corporation, please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.
Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's . The company disclaims any intent or obligation to update these forward-looking statements.
Erik Schwiebert, Ph.D., CEO
International Stem Cell Corporation
Jeffrey Janus, President
The Investor Relations Group
Adam S. Holdsworth